Efficacy and Safety of Fractional CO2 Laser Combined With Intralesional Insulin, Botulinum Toxin or Triamcinolone Acetonide in the Treatment of Keloid: A Clinical, Dermoscopic and Immunohistochemical Study.

Launched by ASSIUT UNIVERSITY · Jan 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for keloids, which are raised scars that can form after an injury and may cause pain or itching. Researchers want to see how effective a combination of a special laser treatment with injections of insulin, botulinum toxin (often known for its cosmetic uses), or a steroid called triamcinolone acetonide can be in reducing keloids. The trial is in its early stages and has not started recruiting participants yet.

To be eligible for the study, participants need to be at least 10 years old and have a diagnosed keloid that is less than 10 square centimeters in size. However, individuals who are pregnant, have certain medical conditions like diabetes or liver disease, or have had recent treatments for keloids will not be able to join. If you participate, you can expect to receive the combination treatment and be monitored for its effectiveness and safety. This trial aims to find better ways to manage keloids, which can be a challenging condition for many people.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged equal or more than 10 years old
• • with keloids diagnosed clinically
• • with any size less than 10 cm2
• Exclusion Criteria:
• • Pregnancy
• • Hypertrophic scars
• • Diabetes mellitus
• • Kidney or liver disease
• • Active infection at site of lesion
• • Lesions suspicious for malignancy
• • Patients use medications that reduced tissue healing during the study or in a period less than sex months ago (immunosuppressants and isotretinoin)
• • Patients received any treatment for keloid in the last 3 months